Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
enGene Therapeutics Inc. - Common Stock
(NQ:
ENGN
)
1.790
+0.020 (+1.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about enGene Therapeutics Inc. - Common Stock
< Previous
1
2
Next >
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Via
The Motley Fool
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
↗
May 15, 2026
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Are EnGene Holdings Shares Trading Lower Friday?
↗
June 14, 2024
EnGene Holdings Inc. shares are trading lower Friday after the company, reported its financial results for the second quarter.
Via
Benzinga
Unusual volume stocks are being observed in Monday's session.
↗
May 11, 2026
Via
Chartmill
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
↗
May 08, 2026
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk...
Via
MarketBeat
Which stocks are experiencing notable movement on Thursday?
↗
May 07, 2026
Via
Chartmill
Top stock movements in today's session.
↗
May 07, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 07, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Thursday?
↗
May 07, 2026
Via
Chartmill
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
↗
March 21, 2026
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 18, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 13, 2025
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session.
↗
November 11, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
November 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
↗
November 11, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 11, 2025
Via
Benzinga
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial
↗
November 11, 2025
enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 11, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday
↗
November 11, 2025
Via
Benzinga
ENGN Stock Soars On Hopeful Data From Bladder Cancer Study
↗
November 11, 2025
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.
Via
Stocktwits
Get insights into the top gainers and losers of Tuesday's pre-market session.
↗
November 11, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles
↗
September 11, 2025
enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation.
Via
Chartmill
enGene Posts 78% Expense Jump in Q3
↗
September 11, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
August 28, 2025
Via
Benzinga
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
February 18, 2025
Via
Benzinga
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
November 18, 2024
Via
Benzinga
Why enGene Holdings Stock Is Trading Higher
↗
October 25, 2024
enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.
Via
Benzinga
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
October 24, 2024
Via
Benzinga
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
↗
June 14, 2024
ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
